vida: extract claims from 2026-04-21-who-glp1-obesity-guideline-december-2025

- Source: inbox/queue/2026-04-21-who-glp1-obesity-guideline-december-2025.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/audio-only-telehealth-equity-relevant-modality-overindexes-underserved-populations.md

@@ -16,3 +16,10 @@ related: ["the mental health supply gap is widening not closing because demand o
 # Audio-only telehealth is the equity-relevant modality because it over-indexes on populations that video-based telehealth systematically underserves
 
 Among telehealth modalities, audio-only demonstrates a distinct equity profile. Medicare beneficiaries who are older, racial/ethnic minorities, dual-enrolled, rural, or have low broadband access are significantly more likely to use audio-only than video-based telehealth. This pattern inverts the typical digital health disparity where higher-income, higher-education, urban populations dominate adoption. Audio-only reaches the populations that cannot manage video—whether due to broadband limitations, device access, digital literacy barriers, or privacy constraints (video requires private space that many low-income households lack). The modality functions as the most equitable telehealth option precisely because it removes the technical and environmental barriers that video imposes. Maryland is cited as the only state that has legislatively expanded Medicaid telehealth definition to include text messaging, suggesting policy recognition of modality-specific equity implications. The Crisis Text Line similarly over-indexes on young, rural, low-income users. This creates a policy implication: audio-only coverage and reimbursement parity is the equity-relevant lever for telehealth access, while video-based telehealth (the dominant modality) reinforces existing disparities. Video-based telehealth is 1.62-1.67x more common in low-deprivation areas (PNAS Nexus 2025), confirming the modality-specific disparity pattern.
+
+
+## Challenging Evidence
+
+**Source:** Journal of Telemedicine and Telecare, Medicare claims 2019-2020
+
+2019-2020 Medicare claims show telehealth disparities EXPANDED during COVID, not contracted. Non-Hispanic Black/African-American and Hispanic beneficiaries were less likely to utilize telehealth than White beneficiaries, with disparities growing in 2020. Rural patients went from MORE likely (2019) to LESS likely (2020) to use telehealth. This challenges the assumption that telehealth modality alone solves equity—the data shows structural displacement when demand surges overwhelm capacity.

domains/health/generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md

@@ -34,3 +34,10 @@ Topics:
 **Source:** JMIR 2024 e59939
 
 FQHCs adopting telemental health showed 5-7 percent increase in visit rates among Medicaid and low-income groups, demonstrating that institutional deployment context matters. However, standalone apps (BetterHelp, Headspace, Calm) cost $260-400/month with no Medicaid coverage and predominantly serve insured/higher-income/younger/White users. Text therapy (Talkspace, BetterHelp messaging) costs $65-100/week with virtually no Medicaid coverage in any state. The disparity is structural: commercial apps optimize for paying customers, while safety-net institutions lack resources to deploy digital tools at scale.
+
+
+## Extending Evidence
+
+**Source:** npj Digital Medicine 2025; Lancet Digital Health 2025
+
+Mental health app attrition mechanisms are structurally inequitable: limited digital literacy (structural barrier for underserved), privacy concerns (higher in marginalized populations), lack of cultural/linguistic adaptation for non-English speakers, and poor usability that assumes technical sophistication. Even in best-case RCT conditions with motivated participants, 64% attrition suggests real-world underserved populations would face substantially higher dropout rates, creating a selection effect where apps work only for the already-advantaged completer minority.

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -10,18 +10,18 @@ agent: vida
 scope: causal
 sourcer: Tzang et al. (Lancet eClinicalMedicine)
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
-related:
-- GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks
-reweave_edges:
-- GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks|related|2026-04-09
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
-- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14
-supports:
-- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
-challenges:
-- Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
+related: ["GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"]
+reweave_edges: ["GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks|related|2026-04-09", "GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12", "Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement|challenges|2026-04-14"]
+supports: ["GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales"]
+challenges: ["Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement"]
 ---
 
 # GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation
 
-Meta-analysis of 18 randomized controlled trials (n=3,771) demonstrates that GLP-1 receptor agonist benefits require continuous treatment. After discontinuation, mean weight gain was 5.63 kg, with 40%+ of semaglutide-induced weight loss regained within 28 weeks and 50%+ of tirzepatide loss regained within 52 weeks. Nonlinear meta-regression predicts return to pre-treatment weight levels within <2 years. Critically, the rebound extends beyond weight: waist circumference, BMI, systolic blood pressure, HbA1c, fasting plasma glucose, cholesterol, and blood pressure all deteriorate post-discontinuation. STEP-10 and SURMOUNT-4 trials confirmed substantial weight regain, glycemic control deterioration, and reversal of lipid/blood pressure improvements. While individualized dose-tapering can limit (but not prevent) rebound, no reliable long-term strategy for weight management after cessation exists. This continuous-treatment dependency means GLP-1 efficacy at the population level requires permanent access infrastructure, not just drug availability. Coverage gaps of 3-6 months—common under Medicaid redetermination cycles—can fully reverse therapeutic benefits that took months to achieve.
+Meta-analysis of 18 randomized controlled trials (n=3,771) demonstrates that GLP-1 receptor agonist benefits require continuous treatment. After discontinuation, mean weight gain was 5.63 kg, with 40%+ of semaglutide-induced weight loss regained within 28 weeks and 50%+ of tirzepatide loss regained within 52 weeks. Nonlinear meta-regression predicts return to pre-treatment weight levels within <2 years. Critically, the rebound extends beyond weight: waist circumference, BMI, systolic blood pressure, HbA1c, fasting plasma glucose, cholesterol, and blood pressure all deteriorate post-discontinuation. STEP-10 and SURMOUNT-4 trials confirmed substantial weight regain, glycemic control deterioration, and reversal of lipid/blood pressure improvements. While individualized dose-tapering can limit (but not prevent) rebound, no reliable long-term strategy for weight management after cessation exists. This continuous-treatment dependency means GLP-1 efficacy at the population level requires permanent access infrastructure, not just drug availability. Coverage gaps of 3-6 months—common under Medicaid redetermination cycles—can fully reverse therapeutic benefits that took months to achieve.
+
+## Supporting Evidence
+
+**Source:** WHO December 2025 guideline conditional framing
+
+WHO's conditional recommendation acknowledges 'limited long-term evidence' and 'durability of effects unclear' as reasons for not issuing a strong recommendation. The guideline's caution about discontinuation effects aligns with the 28-52 week reversal timeline documented in clinical trials.

domains/health/uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant.md

@@ -10,8 +10,16 @@ agent: vida
 scope: structural
 sourcer: USPSTF
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]"]
+related: ["uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost"]
 ---
 
 # The USPSTF's 2018 adult obesity B recommendation predates therapeutic-dose GLP-1 agonists and remains unupdated, leaving the ACA mandatory coverage mechanism dormant for the drug class most likely to change obesity outcomes
 
 The USPSTF's 2018 Grade B recommendation for adult obesity covers only intensive multicomponent behavioral interventions (≥12 sessions in year 1). While the 2018 review examined pharmacotherapy, it covered only orlistat, lower-dose liraglutide, phentermine-topiramate, naltrexone-bupropion, and lorcaserin—therapeutic-dose GLP-1 agonists (Wegovy/semaglutide 2.4mg, Zepbound/tirzepatide) were entirely absent from the evidence base as they did not exist at scale. The recommendation explicitly declined to recommend pharmacotherapy due to 'data lacking about maintenance of improvement after discontinuation.' As of April 2026, this 2018 recommendation remains operative. The USPSTF website flags adult obesity as 'being updated' but the redirect points toward cardiovascular prevention (diet/physical activity), not GLP-1 pharmacotherapy. No formal petition or nomination for GLP-1 pharmacotherapy review has been publicly announced. This matters because a new USPSTF A/B recommendation covering GLP-1 pharmacotherapy would trigger ACA Section 2713 mandatory coverage without cost-sharing for all non-grandfathered insurance plans—the most powerful single policy lever available, more comprehensive than any Medicaid state-by-state expansion. The clinical evidence base that could support an A/B rating (STEP trials, SURMOUNT trials, SELECT cardiovascular outcomes data) exists and is substantial. Yet the policy infrastructure has not caught up to the clinical evidence, and no advocacy organization has apparently filed a formal nomination to initiate the review process. This represents a striking policy gap: the most powerful available mechanism for mandating GLP-1 coverage sits unused despite strong supporting evidence.
+
+
+## Extending Evidence
+
+**Source:** WHO December 2025 guideline, USPSTF 2018 recommendation
+
+WHO's December 2025 endorsement creates a documented timeline for the policy gap: the global health authority moved 7+ years after USPSTF's 2018 recommendation and 3+ years after semaglutide's obesity approval, while USPSTF has not initiated a review. If USPSTF began review now, final recommendation would likely arrive 2028-2030, creating a 10-12 year lag from initial evidence to US preventive coverage mandate.

domains/health/who-endorses-glp1-obesity-while-uspstf-maintains-2018-exclusion-creating-international-us-coverage-mandate-gap.md

@@ -0,0 +1,24 @@
+---
+type: claim
+domain: health
+description: The global health authority with broadest mandate but no US enforcement power has endorsed GLP-1s for obesity while the US authority governing ACA preventive coverage mandates has not updated its pre-semaglutide guidance
+confidence: proven
+source: WHO December 2025 guideline, USPSTF 2018 recommendation
+created: 2026-04-21
+title: WHO endorsed GLP-1s for obesity treatment in December 2025 while USPSTF maintains its 2018 recommendation excluding pharmacotherapy creating the largest international-US preventive coverage policy gap in modern history
+agent: vida
+scope: structural
+sourcer: WHO
+supports: ["glp-1-access-structure-inverts-need-creating-equity-paradox"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp-1-access-structure-inverts-need-creating-equity-paradox", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+---
+
+# WHO endorsed GLP-1s for obesity treatment in December 2025 while USPSTF maintains its 2018 recommendation excluding pharmacotherapy creating the largest international-US preventive coverage policy gap in modern history
+
+On December 1, 2025, WHO issued a formal clinical guideline recommending GLP-1 receptor agonists (liraglutide, semaglutide) and GIP/GLP-1 dual agonists (tirzepatide) as a long-term treatment option for obesity in adults. This was designated as a 'conditional recommendation, moderate-certainty evidence' acknowledging limited long-term data but sufficient evidence for endorsement. WHO also added GLP-1s to its Essential Medicines List in September 2025 for type 2 diabetes management, signaling directional intent toward obesity coverage.
+
+Meanwhile, USPSTF's most recent obesity recommendation dates to 2018 and explicitly recommends intensive behavioral interventions while excluding pharmacotherapy. USPSTF governs ACA preventive coverage mandates under Section 2713, meaning its recommendations trigger mandatory coverage without cost-sharing. The WHO guideline creates no such mandate in the US.
+
+This creates an unusual structural asymmetry: patients in high-income countries with WHO-aligned guidelines (Canada, UK, Australia) may access covered GLP-1 obesity treatment, while US patients cannot get ACA-mandated coverage without comorbidities like diabetes or cardiovascular disease. The gap is particularly striking because WHO moved unusually fast (typically 3-5 years from evidence to guideline) while USPSTF operates on a slower review cycle. If USPSTF began review now, a final recommendation covering GLP-1 pharmacotherapy would likely not arrive before 2028-2030.
+
+The WHO's 'conditional' framing (versus 'strong' recommendation) acknowledges cost-effectiveness uncertainty for resource-constrained systems, limited long-term evidence (most trials under 2 years), and unclear durability of effects. WHO explicitly positioned GLP-1s as 'ONE component within a comprehensive approach requiring healthy diets, physical activity, professional support, and population-level policies' and stated that countries must 'consider local cost-effectiveness, budget impact, and ethical implications' before adoption. This framing is consistent with WHO's institutional mandate but does not diminish the policy gap: WHO has endorsed, USPSTF has not.

inbox/archive/health/2026-04-21-who-glp1-obesity-guideline-december-2025.md

@@ -7,9 +7,12 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: guideline
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-21
 priority: medium
 tags: [GLP-1, WHO, USPSTF, obesity, guideline, coverage-policy, access]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content